Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases
NCT ID: NCT05188924
Last Updated: 2022-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
158 participants
INTERVENTIONAL
2020-05-22
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of a Liquid Toothpaste on Periodontal Disease
NCT03117153
Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial
NCT05902208
A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
NCT01499225
The Treatment of Periodontal Diseases
NCT01318928
The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH)
NCT02924350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DKF-306
During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
DKF-306
Active ingredients
Placebo
During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DKF-306
Active ingredients
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Periodontal diseases
* Having not less than 16 permanent teeth including at least 4 molars (third molars excluded)
* Having teeth with not less than 2 sites of both probing pocket depth (PPD) ≥ 4 mm and gingival index (GI) ≥ 2 in at least 2 quadrants
* Agrees not to use over-the-counters (oral, ointment, toothpaste, film, etc.) or quasi-drugs (gargle and mouthwash) to alleviate or treat the symptoms of gingivitis or periodontitis during the study
* Voluntarily signed the informed consent form
* Willing to participate in the study
Exclusion Criteria
* Hypersensitivity to Azo dyes, acetylsalicylic acid or other prostaglandin synthase inhibitors
* Following diseases or state in the mouth:
1. rampant caries or decayed tooth/teeth remained untreated for a long time
2. multiple restorations which may be related to periodontal inflammation
3. poor oral hygiene with heavy plaque or calculus deposition
4. soft or hard tissue tumor
5. systemic chronic diseases with oral manifestations
6. fibrotic gingival enlargement
* Use of orthodontic appliances or removable partial denture(s)
* Having teeth or state in need of immediate treatment such as periodontal abscess, a tooth indicated for extraction, etc.
* History of aggressive periodontitis or acute necrotizing ulcerative gingivitis
* Received dental treatments such as endodontic treatments or periodontal therapy (including both nonsurgical and surgical therapy) within 3 months from randomization
* Received the following drugs for more than 2 weeks within 3 months from randomization:
1. systemic/local antibiotics in the mouth or non-steroidal anti-inflammatory drugs
2. cyclosporine or corticosteroids
3. phenytoin, calcium antagonists, anticoagulants or antiplatelets
* Initiated drugs in treatment of chronic diseases within 3 months from randomization
* Received the same drug with investigational products within 3 months from randomization
* Medical conditions or diseases affecting the efficacy and safety of investigational products at the investigator's discretion
* Heavy smoker (20 cigarettes or more a day)
* Pregnant or breast-feeding
* Plans to have a child or unwilling to comply with using medically accepted contraception methods during the study
* Alcohol or drug abuse
* Other investigational products or procedures within 3 months from screening
* Not eligible due to other reasons at the investigator's discretion
19 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongkook Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Youngsung
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DKF-306-P4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.